Partnership to Develop Urea Cycle Disorders Therapy Partnership to Develop Urea Cycle Disorders Therapy Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders
New vaccine against Bovine Respiratory Disease New vaccine against Bovine Respiratory Disease Boehringer Ingelheim’s Bovalto Respi Intranasal is a new respiratory vaccine for active immunization of cattle against Bovine Respiratory Disease.
European Metacam® indication expanded to guinea pigs European Metacam® indication expanded to guinea pigs Boehringer Ingelheim adds a new species to its Metacam® brand in Europe, expanding the indications of this widely-used medicine to guinea pigs.
digital_leader_award_2020 digital_leader_award_2020 Boehringer Ingelheim wins first place in the "STRATEGY" category of the Digital Leader Award
Classical Swine Fever live vaccine approved in China Classical Swine Fever live vaccine approved in China Boehringer Ingelheim’s China-developed Classical Swine Fever live vaccine approved
Research ruminant animal health well-being Research ruminant animal health well-being Boehringer Ingelheim supports young scientists and veterinarians dedicated to ruminant health research
License to develop new fibro-inflammatory disease treatments License to develop new fibro-inflammatory disease treatments License to develop new fibro-inflammatory disease treatments
Quality Quality At Boehringer Ingelheim, Quality is deeply embedded into the lifecycle of the product: from Research and development to the delivery to our patients.
Arti-cell Forte stem cell-based veterinary product Arti-cell Forte stem cell-based veterinary product Boehringer Ingelheim launches the first-ever registered stem cell-based veterinary medicine
LastMile increases access to veterinary care in Africa LastMile increases access to veterinary care in Africa Boehringer Ingelheim’s LastMile initiative reaches over 40,000 smallholder farmers in Sub-Saharan Africa increasing access to veterinary medicine
discontinuation-bi-1467335-diabetic-retinopathy discontinuation-bi-1467335-diabetic-retinopathy The discontinuation of the development of BI 1467335 in diabetic retinopathy has been announced
Awards & International Recognition| Bioxcellence | Boehringer Ingelheim Awards & International Recognition| Bioxcellence | Boehringer Ingelheim Explore Bioxcellence's global recognition, showcasing our prestigious awards & certifications. Witness our commitment to excellence in biopharmaceuticals!
collaboration-kings-college-london collaboration-kings-college-london Boehringer Ingelheim and the IoPPN at King’s College London partner to progress new therapeutic concepts in major depressive disorder and schizophrenia
Innovation from within Innovation from within Justine Rochon and Marc Weimer talk about the transformation of Biostatistics and Data Sciences (BDS) into a modern organisation in drug development.
Innovation in medicinal chemistry Innovation in medicinal chemistry Darryl McConnell, Research Site Head, Austria and Jürgen Mack, Medicinal Chemistry, explain how we are working to unlock unsolved diseases
Production Insights Production Insights Boehringer Ingelheim makes an important contribution to the reliable and sustainable supply of pharmaceuticals
LastMile initiative to address barriers in animal healthcare LastMile initiative to address barriers in animal healthcare The ‘LastMile’ initiative addresses major barriers in animal healthcare sector in Sub-Saharan African
Biopharmaceutical Contract Manufacturing | Bioxcellence | Boehringer Ingelheim Biopharmaceutical Contract Manufacturing | Bioxcellence | Boehringer Ingelheim Meet BioXcellence - your trusted partner for top-quality biopharmaceutical development & manufacturing. Experience our world-class service. Contact us.
environmental sustainability commitments environmental sustainability commitments On the occasion of the 2021 UN Climate Change Conference (COP26), Boehringer Ingelheim shares an update on its strategic approach to sustainability
New biomass power plant Ingelheim New biomass power plant Ingelheim Boehringer Ingelheim produces its own green energy
cat feline diabetes medication treatment fda approval cat feline diabetes medication treatment fda approval Boehringer Ingelheim receives FDA approval for SENVELGO®
Building blocks of our future Building blocks of our future Our global investment projects are the building blocks for improved healthcare and sustainability
IL-11 inhibitor antibody clinical development launched IL-11 inhibitor antibody clinical development launched Boehringer Ingelheim has launched clinical development of its first-in-class IL-11 inhibitor antibody as a fibrotic disease treatment
Aseptic filling services | Bioxcellence | Boehringer Ingelheim Aseptic filling services | Bioxcellence | Boehringer Ingelheim Discover top-notch aseptic processing for biopharmaceuticals with our filling services, specializing in freeze-dried products & liquids.
Celebrating 20 years of Metacam for cattle Celebrating 20 years of Metacam for cattle Celebrating 20 years of Metacam (Meloxicam) for cattle